The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat

Musbah O M Tanira, Brian L. Furman

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Many reports suggest that extrapancreatic actions contribute to the antidiabetic effect of sulphonylurea drugs (SUs). In this work, the ability of two SUs, namely, gliclazide and glibenclamide, to augment insulin action was studied in vivo. Both drugs elevated the plasma concentration of immunoreactive insulin (IRI) and lowered the plasma concentrations of glucose and non-esterified fatty acids (NEFA) in normal intact rats. These changes were not reproduced in alloxan-diabetic or eviscerated rats. The actions of insulin on plasma glucose and NEFA were not augmented by gliclazide in alloxan-diabetic rats. Neither gliclazide nor glibenclamide (given acutely and for 30 days) augmented the actions of exogenously administered insulin in reducing plasma glucose or NEFA concentrations in intact or eviscerated animals. It was concluded that these SUs do not produce their acute or chronic effects on blood glucose by augmenting the actions of insulin.

Original languageEnglish
Pages (from-to)349-356
Number of pages8
JournalPharmacological Research
Volume39
Issue number5
DOIs
Publication statusPublished - May 1999

Fingerprint

Gliclazide
Glyburide
Insulin
Glucose
Alloxan
Fatty Acids
Pharmaceutical Preparations
Hypoglycemic Agents
Blood Glucose

Keywords

  • Extrapancreatic
  • Glibenclamide
  • Gliclazide
  • Insulin
  • Metabolism

ASJC Scopus subject areas

  • Pharmacology

Cite this

The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat. / Tanira, Musbah O M; Furman, Brian L.

In: Pharmacological Research, Vol. 39, No. 5, 05.1999, p. 349-356.

Research output: Contribution to journalArticle

@article{8da051055f6248e8afd8882e74282381,
title = "The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat",
abstract = "Many reports suggest that extrapancreatic actions contribute to the antidiabetic effect of sulphonylurea drugs (SUs). In this work, the ability of two SUs, namely, gliclazide and glibenclamide, to augment insulin action was studied in vivo. Both drugs elevated the plasma concentration of immunoreactive insulin (IRI) and lowered the plasma concentrations of glucose and non-esterified fatty acids (NEFA) in normal intact rats. These changes were not reproduced in alloxan-diabetic or eviscerated rats. The actions of insulin on plasma glucose and NEFA were not augmented by gliclazide in alloxan-diabetic rats. Neither gliclazide nor glibenclamide (given acutely and for 30 days) augmented the actions of exogenously administered insulin in reducing plasma glucose or NEFA concentrations in intact or eviscerated animals. It was concluded that these SUs do not produce their acute or chronic effects on blood glucose by augmenting the actions of insulin.",
keywords = "Extrapancreatic, Glibenclamide, Gliclazide, Insulin, Metabolism",
author = "Tanira, {Musbah O M} and Furman, {Brian L.}",
year = "1999",
month = "5",
doi = "10.1006/phrs.1998.0446",
language = "English",
volume = "39",
pages = "349--356",
journal = "Pharmacological Research",
issn = "1043-6618",
publisher = "Academic Press Inc.",
number = "5",

}

TY - JOUR

T1 - The in vivo interaction between gliclazide and glibenclamide and insulin on glucose disposal in the rat

AU - Tanira, Musbah O M

AU - Furman, Brian L.

PY - 1999/5

Y1 - 1999/5

N2 - Many reports suggest that extrapancreatic actions contribute to the antidiabetic effect of sulphonylurea drugs (SUs). In this work, the ability of two SUs, namely, gliclazide and glibenclamide, to augment insulin action was studied in vivo. Both drugs elevated the plasma concentration of immunoreactive insulin (IRI) and lowered the plasma concentrations of glucose and non-esterified fatty acids (NEFA) in normal intact rats. These changes were not reproduced in alloxan-diabetic or eviscerated rats. The actions of insulin on plasma glucose and NEFA were not augmented by gliclazide in alloxan-diabetic rats. Neither gliclazide nor glibenclamide (given acutely and for 30 days) augmented the actions of exogenously administered insulin in reducing plasma glucose or NEFA concentrations in intact or eviscerated animals. It was concluded that these SUs do not produce their acute or chronic effects on blood glucose by augmenting the actions of insulin.

AB - Many reports suggest that extrapancreatic actions contribute to the antidiabetic effect of sulphonylurea drugs (SUs). In this work, the ability of two SUs, namely, gliclazide and glibenclamide, to augment insulin action was studied in vivo. Both drugs elevated the plasma concentration of immunoreactive insulin (IRI) and lowered the plasma concentrations of glucose and non-esterified fatty acids (NEFA) in normal intact rats. These changes were not reproduced in alloxan-diabetic or eviscerated rats. The actions of insulin on plasma glucose and NEFA were not augmented by gliclazide in alloxan-diabetic rats. Neither gliclazide nor glibenclamide (given acutely and for 30 days) augmented the actions of exogenously administered insulin in reducing plasma glucose or NEFA concentrations in intact or eviscerated animals. It was concluded that these SUs do not produce their acute or chronic effects on blood glucose by augmenting the actions of insulin.

KW - Extrapancreatic

KW - Glibenclamide

KW - Gliclazide

KW - Insulin

KW - Metabolism

UR - http://www.scopus.com/inward/record.url?scp=0033136380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033136380&partnerID=8YFLogxK

U2 - 10.1006/phrs.1998.0446

DO - 10.1006/phrs.1998.0446

M3 - Article

C2 - 10328992

AN - SCOPUS:0033136380

VL - 39

SP - 349

EP - 356

JO - Pharmacological Research

JF - Pharmacological Research

SN - 1043-6618

IS - 5

ER -